Are peptides legal in the US?

Why there is no single answer

• Approved drugs. Numerous peptide drugs have been through FDA approval, which evaluates safety and efficacy, while a parallel “gray market” of unapproved compounds has grown up alongside (Mendias & Awan, 2026).
• Unapproved compounds. BPC-157 lacks FDA approval, and its use is banned in professional sport (Vasireddi et al., 2025).
• Pharmacy compounding. A licensed pharmacy may compound a drug for an individual patient only under conditions set by FDA. One of them is that the bulk substance is on, or covered by FDA's policy for, its bulks lists. This is where most 2026 changes happened.
• Supplements, cosmetics and “research use only” products. These follow different rules and are not covered on this page.

What happened, in order

1. 29 September 2023

   FDA adds several peptides to Category 2 of its interim compounding policies, its list of bulk substances that may present significant safety risks. FDA's page dates the entries for GHRP-2, GHRP-6, ipamorelin acetate and kisspeptin-10 to this day.

   Sources: FDA / federal source

2. 16 April 2026

   FDA publishes notice of a public meeting of its Pharmacy Compounding Advisory Committee on 23 and 24 July 2026, to advise on bulk drug substances nominated for the Section 503A bulks list, and opens a public docket (FDA-2025-N-6895).

   Sources: FDA / federal source

3. As of 22 April 2026

   FDA's Category 2 page lists BPC-157, CJC-1295, GHK-Cu (injectable routes), KPV, MOTS-c, selank, semax, thymosin alpha-1, TB-500, epitalon and emideltide (DSIP), among others, as substances that were previously in Category 2 and were withdrawn by the nominators. Ipamorelin acetate appears on that list too, and the page also keeps it in Category 2 for 503B. For several of these, FDA's stated concerns include the risk of an immune reaction and difficulty characterising the peptide and its impurities.

   Sources: FDA / federal source

4. 23 and 24 July 2026

   The advisory committee meets and considers seven peptides for the 503A bulks list (see the table below). According to news reports, it recommended six and rejected one. FDA's own meeting page, current as of 6 August 2026 when we read it, carried the agenda and briefing materials but not the votes.

   Sources: FDA / federal source; News report; News report

The July 2026 committee meeting

FDA's Pharmacy Compounding Advisory Committee reviewed seven peptides nominated for the 503A bulks list. The uses listed are the ones FDA's meeting page says were evaluated; the results are as reported by news outlets.

• The BPC-157 vote was reported as 8 in favour, 6 against and 1 abstention. TIME gives the full count only for BPC-157.
• The recommendation is not binding. FDA decides, and adding a substance to the list would require a public rulemaking process, which ABC News reports can take up to a year.
• FDA staff had recommended against listing. TIME reports that staff said the criteria weighed against BPC-157 and KPV, citing limited evidence of effectiveness and, for KPV, no human studies; ABC News reports that staff opposed all seven.

Sources: FDA / federal source; News report; News report

What this does and does not mean

• A committee vote is advice, not a decision. In our searches we found no later FDA proposed rule or final decision on these peptides.
• Being allowed to be compounded is not the same as being approved, and it is not evidence that a peptide works. FDA's own Category 2 page cites concerns for several of these peptides, including the risk of an immune reaction and difficulty characterising the peptide and its impurities. For what the studies show, see the safety evidence and the joints and tendons evidence.
• Nothing on this page tells you what is lawful in your own situation. It is not legal advice.

Not covered here yet

• HHS has published an interim enforcement-discretion policy for certain peptides under Section 503A (Appendix B). We could not open the document directly when this page was written, so we have not summarised its conditions. Read it before relying on this page for anything HHS-related.
• Rules for dietary supplements, cosmetics and products sold as “research use only”.
• Rules outside the United States.

Sources

• FDA: Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (Category 2) FDA / federal
• Federal Register notice 2026-07361: Pharmacy Compounding Advisory Committee meeting and docket FDA-2025-N-6895 FDA / federal
• FDA: July 23-24, 2026 meeting of the Pharmacy Compounding Advisory Committee FDA / federal
• FDA: Briefing document introduction, Pharmacy Compounding Advisory Committee, July 23-24, 2026 FDA / federal
• HHS: 503A peptide enforcement discretion policy, Appendix B FDA / federal
• ABC News: FDA advisers narrowly vote to add 6 peptides to a drug compounding list (24 July 2026) News
• TIME: An FDA Committee Just Voted in Favor of Peptides—Despite the Agency's Opposition (23 July 2026) News